1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 26, 03/Jul/2025
  4. Article
Editorial Open Access
Like 0
Download

SDG 3: STI

Preview this article:
Preview Magnify

There is no abstract available.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.26.2500454
2025-07-03
2025-07-04
/content/10.2807/1560-7917.ES.2025.30.26.2500454
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/26/eurosurv-30-26-1.html?itemId=/content/10.2807/1560-7917.ES.2025.30.26.2500454&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). STI cases continue to rise across Europe. Stockholm: ECDC; 10 Feb 2025. Available from: https://www.ecdc.europa.eu/en/news-events/sti-cases-continue-rise-across-europe
  2. World Health Organization (WHO). Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. Geneva: WHO; 2022. Available from: https://www.who.int/publications/i/item/9789240053779
  3. Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018;18(3):308-17.  https://doi.org/10.1016/S1473-3099(17)30725-9  PMID: 29229440 
  4. Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, et al. Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections. N Engl J Med. 2023;388(14):1296-306.  https://doi.org/10.1056/NEJMoa2211934  PMID: 37018493 
  5. Molina JM, Bercot B, Assoumou L, Rubenstein E, Algarte-Genin M, Pialoux G, et al. Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design. Lancet Infect Dis. 2024;24(10):1093-104.  https://doi.org/10.1016/S1473-3099(24)00236-6  PMID: 38797183 
  6. Raccagni AR, Diotallevi S, Lolatto R, Bruzzesi E, Catalano G, Mainardi I, et al. DoxyPEP: real-life effectiveness in a cohort of men who have sex with men in Milan, Italy. Lancet Infect Dis. 2025;25(1):e1-3.  https://doi.org/10.1016/S1473-3099(24)00726-6  PMID: 39577454 
  7. Saunders J, Deering J, Dewsnap C, Drayton R, Gilmore J, Grant A, et al. British Association for Sexual Health and HIV (BASHH) UK national guideline for the use of doxycycline post-exposure prophylaxis (DoxyPEP) for the prevention of syphilis, 2025. Int J STD AIDS. 2025:9564624251352053.  https://doi.org/10.1177/09564624251352053  PMID: 40505019 
  8. Bachmann LH, Barbee LA, Chan P, Reno H, Workowski KA, Hoover K, et al. CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024. MMWR Recomm Rep. 2024;73(2):1-8.  https://doi.org/10.15585/mmwr.rr7302a1  PMID: 38833414 
  9. Cornelisse VJ, Riley B, Medland NA. Australian consensus statement on doxycycline post-exposure prophylaxis (doxy-PEP) for the prevention of syphilis, chlamydia and gonorrhoea among gay, bisexual and other men who have sex with men. Med J Aust. 2024;220(7):381-6.  https://doi.org/10.5694/mja2.52258  PMID: 38479437 
  10. Werner RN, Schmidt AJ, Potthoff A, Spornraft-Ragaller P, Brockmeyer NH, German STI, et al. Position statement of the German STI Society on the prophylactic use of doxycycline to prevent STIs (Doxy-PEP, Doxy-PrEP). J Dtsch Dermatol Ges. 2024;22(3):466-78.  https://doi.org/10.1111/ddg.15282  PMID: 38123738 
  11. SOAIDS Nederland SOAIDS. Nederlandse stellingname inzake doxyPEP. [Dutch position on doxyPEP]. Amsterdam: SOAIDS Nederland; Jan 2025. Dutch. Available from: https://www.soaaids.nl/files/2025-01/Nederlandse%20stellingname%20DoxyPEP%20jan2025%20DEFINITIEF%20webversie.pdf
  12. Sherrard J, Gokengin D, Winter A, Marks M, Unemo M, Jensen JS, et al. IUSTI Europe position statement on use of DoxyPEP: June 2024. Int J STD AIDS. 2024;35(13):1087-9.  https://doi.org/10.1177/09564624241273801  PMID: 39167417 
  13. World Health Organization (WHO). WHO announces the development of recommendations on doxycycline prophylaxis for the prevention of sexually transmitted infections. Geneva: WHO; 28 May 2025. Available from: https://www.who.int/news/item/28-05-2025-who-announces-the-development-of-recommendations-on-doxycycline-prophylaxis-for-the-prevention-of-sexually-transmitted-infections#:~:text=WHO%20is%20convening%20a%20Guideline,sexually%20transmitted%20infections%20(STIs)
  14. Mårdh O, Plachouras D. Using doxycycline for prophylaxis of bacterial sexually transmitted infections: considerations for the European Union and European Economic Area. Euro Surveill. 2023;28(46):2300621.  https://doi.org/10.2807/1560-7917.ES.2023.28.46.2300621  PMID: 37971658 
  15. Teker B, Hoornenborg E, Schim van der Loeff MF, Boyd A, Heijne JCM, Prins M, et al. Emergent informal use of doxycycline post- and pre-exposure prophylaxis among men who have sex with men and transgender and gender diverse people, the Netherlands, 2024. Euro Surveill. 2025;30(26):2400707.  https://doi.org/10.2807/1560-7917.ES.2025.30.26.2400707 
  16. Tsoumanis A, Hens N, Kenyon CR. Is Screening for Chlamydia and Gonorrhea in Men Who Have Sex With Men Associated With Reduction of the Prevalence of these Infections? A Systematic Review of Observational Studies. Sex Transm Dis. 2018;45(9):615-22.  https://doi.org/10.1097/OLQ.0000000000000824  PMID: 29485537 
  17. Williams E, Williamson DA, Hocking JS. Frequent screening for asymptomatic chlamydia and gonorrhoea infections in men who have sex with men: time to re-evaluate? Lancet Infect Dis. 2023;23(12):e558-66.  https://doi.org/10.1016/S1473-3099(23)00356-0  PMID: 37516129 
  18. Van Praet JT, Henrard S, Kenyon C, Libois A, Meuwissen A, Sauvage AS, et al. Belgian 2024 guidance on the use of pre-exposure prophylaxis. Acta Clin Belg. 2024;79(2):121-9.  https://doi.org/10.1080/17843286.2024.2356337  PMID: 38775082 
  19. National Institute for Public Health and the Environment (RIVM). 11-7-2024 Verandering testbeleid Chlamydia. [11-7-2024 Change in Chlamydia testing policy]. Bilthoven: RIVM; 11 Jul 2024. Dutch. Available from: https://www.rivm.nl/soa/actueel
  20. Fredericksen RJ, Perkins R, Brown CE, Cannon C, Lopez C, Cohee A, et al. Doxycycline as Postsexual Exposure Prophylaxis: Use, Acceptability, and Associated Sexual Health Behaviors Among a Multi-Site Sample of Clinical Trial Participants. AIDS Patient Care STDs. 2024;38(4):155-67.  https://doi.org/10.1089/apc.2023.0289  PMID: 38656217 
  21. Chan PA, Malyuta Y, Parent H, Tao J, Erbe M, Salhaney P, et al. Early adopters of doxycycline as post-exposure prophylaxis to prevent bacterial sexually transmitted infections in a real-world clinical setting. Sex Transm Infect. 2024;100(6):339-42.  https://doi.org/10.1136/sextrans-2024-056152  PMID: 38821877 
  22. Villanueva Baselga S, Ruben M, Luis V. A practice already in use: a snapshot survey on the use of doxycycline as a preventive strategy (Doxy-PEP and Doxy-PrEP) in the GBMSM population in Spain. Infection. 2025;53(1):437-41.  https://doi.org/10.1007/s15010-024-02320-y  PMID: 39060908 
  23. Ehsan R, D’Angelo AB, Westmoreland DA, Grov C. Perceptions about doxycycline post-exposure prophylaxis (Doxy-PEP) as an STI-prevention strategy among gay and bisexual men (GBM) in the United States: Results from a qualitative study. Prev Med. 2024;183:107977.  https://doi.org/10.1016/j.ypmed.2024.107977  PMID: 38692309 
  24. Horn R, Callander D, Haire B. Perceptions of sexually transmissible infection pre-exposure prophylaxis: a qualitative study of high-risk gay and bisexual men in Sydney, New South Wales. Sex Health. 2020;17(2):129-34.  https://doi.org/10.1071/SH19175  PMID: 32213272 
  25. Dillon C, O’Donnell K, McKeown P, Lyons F, Browne C, Fallon U, et al. Mpox outbreak - Response and epidemiology of confirmed cases in Ireland from May 2022 to May 2023. Ir Med J. 2024;117(6):975. PMID: 39041467 
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error